Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs.

The global Neutropenia Biologic Drug Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Neutropenia Biologic Drug Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neutropenia Biologic Drug Treatment.

Report Scope

The Neutropenia Biologic Drug Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neutropenia Biologic Drug Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neutropenia Biologic Drug Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neutropenia Biologic Drug Treatment Market Report

Report Metric	Details
Report Name	Neutropenia Biologic Drug Treatment Market
CAGR	5%
Segment by Type	By Drug Type Filgrastim Pegfilgrastim Lenograstim Lipegfilgrastim Sargramostim By Treatment Type Antibiotic Drugs Granulocyte-Colony-Stimulating Factor (G-CSF) Antifungal Drugs Others
Segment by Application	Retail Pharmacies Hospital Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Teva Pharmaceutical, Amgen, Sanofi, Mylan(Fulphila), Kyowa Kirin, Novartis, Spectrum Pharmaceuticals, Pfizer, Baxter International, Partner Therapeutics(Leukine), BeyondSpring Pharmaceuticals, Cellerant Therapeutics, Enzychem Lifesciences Corporation, Myelo Therapeutics, Generon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neutropenia Biologic Drug Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neutropenia Biologic Drug Treatment Market report?

Ans: The main players in the Neutropenia Biologic Drug Treatment Market are Teva Pharmaceutical, Amgen, Sanofi, Mylan(Fulphila), Kyowa Kirin, Novartis, Spectrum Pharmaceuticals, Pfizer, Baxter International, Partner Therapeutics(Leukine), BeyondSpring Pharmaceuticals, Cellerant Therapeutics, Enzychem Lifesciences Corporation, Myelo Therapeutics, Generon

What are the Application segmentation covered in the Neutropenia Biologic Drug Treatment Market report?

Ans: The Applications covered in the Neutropenia Biologic Drug Treatment Market report are Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Neutropenia Biologic Drug Treatment Market report?

Ans: The Types covered in the Neutropenia Biologic Drug Treatment Market report are By Drug Type, Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim, By Treatment Type, Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis By Drug Type

1.2.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate By Drug Type: 2019 VS 2023 VS 2030

1.2.2 Filgrastim

1.2.3 Pegfilgrastim

1.2.4 Lenograstim

1.2.5 Lipegfilgrastim

1.2.6 Sargramostim

1.3 Market by Application

1.3.1 Global Neutropenia Biologic Drug Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Retail Pharmacies

1.3.3 Hospital Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2019-2030)

2.2 Neutropenia Biologic Drug Treatment Growth Trends by Region

2.2.1 Global Neutropenia Biologic Drug Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neutropenia Biologic Drug Treatment Historic Market Size by Region (2019-2024)

2.2.3 Neutropenia Biologic Drug Treatment Forecasted Market Size by Region (2025-2030)

2.3 Neutropenia Biologic Drug Treatment Market Dynamics

2.3.1 Neutropenia Biologic Drug Treatment Industry Trends

2.3.2 Neutropenia Biologic Drug Treatment Market Drivers

2.3.3 Neutropenia Biologic Drug Treatment Market Challenges

2.3.4 Neutropenia Biologic Drug Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue

3.1.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue (2019-2024)

3.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Neutropenia Biologic Drug Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neutropenia Biologic Drug Treatment Revenue

3.4 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio

3.4.1 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neutropenia Biologic Drug Treatment Revenue in 2023

3.5 Neutropenia Biologic Drug Treatment Key Players Head office and Area Served

3.6 Key Players Neutropenia Biologic Drug Treatment Product Solution and Service

3.7 Date of Enter into Neutropenia Biologic Drug Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Neutropenia Biologic Drug Treatment Breakdown Data by Type

4.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Type (2019-2024)

4.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2025-2030)

5 Neutropenia Biologic Drug Treatment Breakdown Data by Application

5.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Application (2019-2024)

5.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neutropenia Biologic Drug Treatment Market Size (2019-2030)

6.2 North America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024)

6.4 North America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neutropenia Biologic Drug Treatment Market Size (2019-2030)

7.2 Europe Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024)

7.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size (2019-2030)

8.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neutropenia Biologic Drug Treatment Market Size (2019-2030)

9.2 Latin America Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024)

9.4 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2019-2030)

10.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Teva Pharmaceutical

11.1.1 Teva Pharmaceutical Company Detail

11.1.2 Teva Pharmaceutical Business Overview

11.1.3 Teva Pharmaceutical Neutropenia Biologic Drug Treatment Introduction

11.1.4 Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.1.5 Teva Pharmaceutical Recent Development

11.2 Amgen

11.2.1 Amgen Company Detail

11.2.2 Amgen Business Overview

11.2.3 Amgen Neutropenia Biologic Drug Treatment Introduction

11.2.4 Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.2.5 Amgen Recent Development

11.3 Sanofi

11.3.1 Sanofi Company Detail

11.3.2 Sanofi Business Overview

11.3.3 Sanofi Neutropenia Biologic Drug Treatment Introduction

11.3.4 Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.3.5 Sanofi Recent Development

11.4 Mylan(Fulphila)

11.4.1 Mylan(Fulphila) Company Detail

11.4.2 Mylan(Fulphila) Business Overview

11.4.3 Mylan(Fulphila) Neutropenia Biologic Drug Treatment Introduction

11.4.4 Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.4.5 Mylan(Fulphila) Recent Development

11.5 Kyowa Kirin

11.5.1 Kyowa Kirin Company Detail

11.5.2 Kyowa Kirin Business Overview

11.5.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Introduction

11.5.4 Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.5.5 Kyowa Kirin Recent Development

11.6 Novartis

11.6.1 Novartis Company Detail

11.6.2 Novartis Business Overview

11.6.3 Novartis Neutropenia Biologic Drug Treatment Introduction

11.6.4 Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.6.5 Novartis Recent Development

11.7 Spectrum Pharmaceuticals

11.7.1 Spectrum Pharmaceuticals Company Detail

11.7.2 Spectrum Pharmaceuticals Business Overview

11.7.3 Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction

11.7.4 Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.7.5 Spectrum Pharmaceuticals Recent Development

11.8 Pfizer

11.8.1 Pfizer Company Detail

11.8.2 Pfizer Business Overview

11.8.3 Pfizer Neutropenia Biologic Drug Treatment Introduction

11.8.4 Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.8.5 Pfizer Recent Development

11.9 Baxter International

11.9.1 Baxter International Company Detail

11.9.2 Baxter International Business Overview

11.9.3 Baxter International Neutropenia Biologic Drug Treatment Introduction

11.9.4 Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.9.5 Baxter International Recent Development

11.10 Partner Therapeutics(Leukine)

11.10.1 Partner Therapeutics(Leukine) Company Detail

11.10.2 Partner Therapeutics(Leukine) Business Overview

11.10.3 Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Introduction

11.10.4 Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.10.5 Partner Therapeutics(Leukine) Recent Development

11.11 BeyondSpring Pharmaceuticals

11.11.1 BeyondSpring Pharmaceuticals Company Detail

11.11.2 BeyondSpring Pharmaceuticals Business Overview

11.11.3 BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction

11.11.4 BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.11.5 BeyondSpring Pharmaceuticals Recent Development

11.12 Cellerant Therapeutics

11.12.1 Cellerant Therapeutics Company Detail

11.12.2 Cellerant Therapeutics Business Overview

11.12.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Introduction

11.12.4 Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.12.5 Cellerant Therapeutics Recent Development

11.13 Enzychem Lifesciences Corporation

11.13.1 Enzychem Lifesciences Corporation Company Detail

11.13.2 Enzychem Lifesciences Corporation Business Overview

11.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Introduction

11.13.4 Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.13.5 Enzychem Lifesciences Corporation Recent Development

11.14 Myelo Therapeutics

11.14.1 Myelo Therapeutics Company Detail

11.14.2 Myelo Therapeutics Business Overview

11.14.3 Myelo Therapeutics Neutropenia Biologic Drug Treatment Introduction

11.14.4 Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.14.5 Myelo Therapeutics Recent Development

11.15 Generon

11.15.1 Generon Company Detail

11.15.2 Generon Business Overview

11.15.3 Generon Neutropenia Biologic Drug Treatment Introduction

11.15.4 Generon Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024)

11.15.5 Generon Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Cellerant Therapeutics

Enzychem Lifesciences Corporation

Teva Pharmaceutical

Mylan(Fulphila)

Spectrum Pharmaceuticals

Partner Therapeutics(Leukine)

BeyondSpring Pharmaceuticals

Myelo Therapeutics

Generon

List of Tables

Table 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Filgrastim

Table 3. Key Players of Pegfilgrastim

Table 4. Key Players of Lenograstim

Table 5. Key Players of Lipegfilgrastim

Table 6. Key Players of Sargramostim

Table 7. Global Neutropenia Biologic Drug Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Neutropenia Biologic Drug Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Neutropenia Biologic Drug Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Neutropenia Biologic Drug Treatment Market Share by Region (2019-2024)

Table 11. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Neutropenia Biologic Drug Treatment Market Share by Region (2025-2030)

Table 13. Neutropenia Biologic Drug Treatment Market Trends

Table 14. Neutropenia Biologic Drug Treatment Market Drivers

Table 15. Neutropenia Biologic Drug Treatment Market Challenges

Table 16. Neutropenia Biologic Drug Treatment Market Restraints

Table 17. Global Neutropenia Biologic Drug Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Neutropenia Biologic Drug Treatment Market Share by Players (2019-2024)

Table 19. Global Top Neutropenia Biologic Drug Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2023)

Table 20. Ranking of Global Top Neutropenia Biologic Drug Treatment Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Neutropenia Biologic Drug Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Neutropenia Biologic Drug Treatment Product Solution and Service

Table 24. Date of Enter into Neutropenia Biologic Drug Treatment Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Neutropenia Biologic Drug Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2019-2024)

Table 28. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2025-2030)

Table 30. Global Neutropenia Biologic Drug Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2019-2024)

Table 32. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2025-2030)

Table 34. North America Neutropenia Biologic Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Neutropenia Biologic Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Neutropenia Biologic Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 49. Teva Pharmaceutical Company Detail

Table 50. Teva Pharmaceutical Business Overview

Table 51. Teva Pharmaceutical Neutropenia Biologic Drug Treatment Product

Table 52. Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 53. Teva Pharmaceutical Recent Development

Table 54. Amgen Company Detail

Table 55. Amgen Business Overview

Table 56. Amgen Neutropenia Biologic Drug Treatment Product

Table 57. Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 58. Amgen Recent Development

Table 59. Sanofi Company Detail

Table 60. Sanofi Business Overview

Table 61. Sanofi Neutropenia Biologic Drug Treatment Product

Table 62. Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 63. Sanofi Recent Development

Table 64. Mylan(Fulphila) Company Detail

Table 65. Mylan(Fulphila) Business Overview

Table 66. Mylan(Fulphila) Neutropenia Biologic Drug Treatment Product

Table 67. Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 68. Mylan(Fulphila) Recent Development

Table 69. Kyowa Kirin Company Detail

Table 70. Kyowa Kirin Business Overview

Table 71. Kyowa Kirin Neutropenia Biologic Drug Treatment Product

Table 72. Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 73. Kyowa Kirin Recent Development

Table 74. Novartis Company Detail

Table 75. Novartis Business Overview

Table 76. Novartis Neutropenia Biologic Drug Treatment Product

Table 77. Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 78. Novartis Recent Development

Table 79. Spectrum Pharmaceuticals Company Detail

Table 80. Spectrum Pharmaceuticals Business Overview

Table 81. Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Product

Table 82. Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 83. Spectrum Pharmaceuticals Recent Development

Table 84. Pfizer Company Detail

Table 85. Pfizer Business Overview

Table 86. Pfizer Neutropenia Biologic Drug Treatment Product

Table 87. Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 88. Pfizer Recent Development

Table 89. Baxter International Company Detail

Table 90. Baxter International Business Overview

Table 91. Baxter International Neutropenia Biologic Drug Treatment Product

Table 92. Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 93. Baxter International Recent Development

Table 94. Partner Therapeutics(Leukine) Company Detail

Table 95. Partner Therapeutics(Leukine) Business Overview

Table 96. Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Product

Table 97. Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 98. Partner Therapeutics(Leukine) Recent Development

Table 99. BeyondSpring Pharmaceuticals Company Detail

Table 100. BeyondSpring Pharmaceuticals Business Overview

Table 101. BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Product

Table 102. BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 103. BeyondSpring Pharmaceuticals Recent Development

Table 104. Cellerant Therapeutics Company Detail

Table 105. Cellerant Therapeutics Business Overview

Table 106. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product

Table 107. Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 108. Cellerant Therapeutics Recent Development

Table 109. Enzychem Lifesciences Corporation Company Detail

Table 110. Enzychem Lifesciences Corporation Business Overview

Table 111. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product

Table 112. Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 113. Enzychem Lifesciences Corporation Recent Development

Table 114. Myelo Therapeutics Company Detail

Table 115. Myelo Therapeutics Business Overview

Table 116. Myelo Therapeutics Neutropenia Biologic Drug Treatment Product

Table 117. Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 118. Myelo Therapeutics Recent Development

Table 119. Generon Company Detail

Table 120. Generon Business Overview

Table 121. Generon Neutropenia Biologic Drug Treatment Product

Table 122. Generon Revenue in Neutropenia Biologic Drug Treatment Business (2019-2024) & (US$ Million)

Table 123. Generon Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neutropenia Biologic Drug Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Neutropenia Biologic Drug Treatment Market Share by Type: 2023 VS 2030

Figure 3. Filgrastim Features

Figure 4. Pegfilgrastim Features

Figure 5. Lenograstim Features

Figure 6. Lipegfilgrastim Features

Figure 7. Sargramostim Features

Figure 8. Global Neutropenia Biologic Drug Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Neutropenia Biologic Drug Treatment Market Share by Application: 2023 VS 2030

Figure 10. Retail Pharmacies Case Studies

Figure 11. Hospital Pharmacies Case Studies

Figure 12. Online Pharmacies Case Studies

Figure 13. Neutropenia Biologic Drug Treatment Report Years Considered

Figure 14. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Neutropenia Biologic Drug Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Neutropenia Biologic Drug Treatment Market Share by Region: 2023 VS 2030

Figure 17. Global Neutropenia Biologic Drug Treatment Market Share by Players in 2023

Figure 18. Global Top Neutropenia Biologic Drug Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Neutropenia Biologic Drug Treatment Revenue in 2023

Figure 20. North America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)

Figure 22. United States Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)

Figure 26. Germany Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Neutropenia Biologic Drug Treatment Market Share by Region (2019-2030)

Figure 34. China Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)

Figure 42. Mexico Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Country (2019-2030)

Figure 46. Turkey Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Teva Pharmaceutical Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 49. Amgen Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 50. Sanofi Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 51. Mylan(Fulphila) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 52. Kyowa Kirin Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 54. Spectrum Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 55. Pfizer Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 56. Baxter International Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 57. Partner Therapeutics(Leukine) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 58. BeyondSpring Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 59. Cellerant Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 60. Enzychem Lifesciences Corporation Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 61. Myelo Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 62. Generon Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions